Immutep Limited (IMMP) Announces Licensing Partner GSK to Discontinue Ulcerative Colitis Phase II Clinical Trial Evaluating GSK2831781

Go back to Immutep Limited (IMMP) Announces Licensing Partner GSK to Discontinue Ulcerative Colitis Phase II Clinical Trial Evaluating GSK2831781
Immtech Pharmaceuticals, Inc. (NASDAQ: IMMP) Delayed: 3.26 -0.02 (0.61%)
Previous Close $3.28    52 Week High $0.01 
Open $3.30    52 Week Low $0.00 
Day High $3.37    P/E N/A 
Day Low $3.20    EPS $0.00 
Volume 668,703